Peter O’Donnell on Muck Rack

Peter O’Donnell

Verified
Brussels
As seen in: APM Health Europe, Wiley Online Library, POLITICO Europe, PetaPixel, The Lancet, City A.M., OncLive, European Urology, Stornoway Gazette, Crime Time, Ticpharma and
Brussels correspondent APM, Europe columnist ACT
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial

|
By Minas P. Economides, Peter O’Donnell , Ajjai S. Alva, Matthew I. Milowsky, Marisa Kollmeier, Scot A. Niglio, Jesse B. Persily, Randy F. Sweis, Tracy Rose, Gopakumar V. Iyer, Daniel E. Spratt, Phillip L. Palmbos, Judith D Goldberg, Tsivia Hochman, Kaitlyn Francese
| European Urology
What does this study add? This study demonstrates that incorporating pembrolizumab into trimodality bladder-preservation therapy is feasible and can achieve high pathologic complete response rates, suggesting meaningful antitumor activity. Importantly, while the 2-yr bladder-intact disease-free survival did not surpass the predefined threshold, durable metastasis-free and overall survival outcomes were observed.
Open in Who Shared Issue with article?

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011

|
By Peter O’Donnell , Yohann Loriot, Tibor Csöszi, Nobuaki Matsubara
| Wiley Online Library
INTRODUCTION Approximately 30%–50% of patients with advanced urothelial carcinoma (UC) are ineligible to receive cisplatin-based chemotherapy because of baseline characteristics such as advanced age, renal dysfunction, poor performance status, and other medical comorbidities.1, 2 Although numerous patients in this population can still receive carboplatin-based treatment, many are deemed ineligible for any cytotoxic platinum-based chemotherapy by their treating physicians.3, 4 Because no...
Open in Who Shared Issue with article?

Les industriels opposés à l'opt-out pour l'espace européen des données de santé

|
By Peter O’Donnell 
| Ticpharma
La Fédération européenne des industries et associations pharmaceutiques (EFPIA) est l'une des 32 organisations européennes du secteur de la santé ayant rencontré des fonctionnaires de l'Union européenne (UE), des représentants des prochaines présidences de l'UE (Belgique puis Hongrie) et l'eurodéputé croate chef de file du Parlement européen sur la proposition, Tomislav Sokol, le 6 septembre.
Open in Who Shared Issue with article?
See all 83 licensed articles (96 Total)

Actions

Share this page

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified